Literature DB >> 22005222

Development and validation of a model that uses enhanced administrative data to predict mortality in patients with sepsis.

Tara Lagu1, Peter K Lindenauer, Michael B Rothberg, Brian H Nathanson, Penelope S Pekow, Jay S Steingrub, Thomas L Higgins.   

Abstract

OBJECTIVE: We aimed to determine whether a sepsis risk-adjustment model that uses only administrative data could be used when other intensive care unit risk-adjustment methods are unavailable.
DESIGN: Cohort study with development and validation cohorts. PATIENTS: The development cohort included 166,931 patients at 309 hospitals that cared for at least 100 patients with sepsis between 2004 and 2006. The validation cohort included 357 adult sepsis patients who were enrolled in Project IMPACT, 2002-2009.
MEASUREMENTS AND MAIN RESULTS: We developed a multilevel mixed-effects logistic regression model to predict mortality at the patient level. Predictors included patient demographics (age, sex, race, insurance type), site and source of sepsis, presence of 25 individual comorbidities, treatment (within the first 2 days of hospitalization) with mechanical ventilation and/or vasopressors, and/or admission to the intensive care unit (within 2 days of hospitalization). We validated this model in 357 sepsis patients who were admitted to the intensive care unit at a single academic medical center and who had a valid Acute Physiology and Chronic Health Evaluation II score, a valid Simplified Acute Physiology Score II, and a valid Mortality Probability Model III score. Overall, 33,192 patients (19.9%) died in the hospital. In the development cohort, the predicted mortality ranged from 0.002 to 0.938 with a mean of 0.199. The model's area under the receiver operating characteristic curve was 0.78. In the validation cohort, all models had modest discriminatory ability and the areas under the receiver operating characteristic curves of all models were statistically similar (Acute Physiology and Chronic Health Evaluation II, 0.71; Simplified Acute Physiology Score II, 0.74; Mortality Probability Model III, 0.69; administrative model, 0.69; p value that the areas under the receiver operating characteristic curves are different, .35). The Hosmer-Lemeshow statistic was significant (p < .01) for Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II, and Mortality Probability Model III but was nonsignificant (p = .11) for the administrative model.
CONCLUSIONS: A sepsis mortality model using detailed administrative data has discrimination similar to and calibration superior to those of existing severity scores that require chart review. This model may be a useful alternative method of severity adjustment for benchmarking purposes or for conducting large, retrospective epidemiologic studies of sepsis patients.

Entities:  

Mesh:

Year:  2011        PMID: 22005222     DOI: 10.1097/CCM.0b013e31822572e3

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  27 in total

1.  Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study.

Authors:  Allan J Walkey; Stephen R Evans; Michael R Winter; Emelia J Benjamin
Journal:  Chest       Date:  2016-01-06       Impact factor: 9.410

2.  Identifying Pediatric Severe Sepsis and Septic Shock: Accuracy of Diagnosis Codes.

Authors:  Fran Balamuth; Scott L Weiss; Matt Hall; Mark I Neuman; Halden Scott; Patrick W Brady; Raina Paul; Reid W D Farris; Richard McClead; Sierra Centkowski; Shannon Baumer-Mouradian; Jason Weiser; Katie Hayes; Samir S Shah; Elizabeth R Alpern
Journal:  J Pediatr       Date:  2015-10-23       Impact factor: 4.406

3.  Response.

Authors:  Allan J Walkey; Michael R Winter; Emelia J Benjamin
Journal:  Chest       Date:  2016-05       Impact factor: 9.410

4.  Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis.

Authors:  Allan J Walkey; Emily K Quinn; Michael R Winter; David D McManus; Emelia J Benjamin
Journal:  JAMA Cardiol       Date:  2016-09-01       Impact factor: 14.676

5.  Real-Time Automated Sampling of Electronic Medical Records Predicts Hospital Mortality.

Authors:  Hargobind S Khurana; Robert H Groves; Michael P Simons; Mary Martin; Brenda Stoffer; Sherri Kou; Richard Gerkin; Eric Reiman; Sairam Parthasarathy
Journal:  Am J Med       Date:  2016-03-24       Impact factor: 4.965

6.  The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis.

Authors:  Tara Lagu; Mihaela S Stefan; Sarah Haessler; Thomas L Higgins; Michael B Rothberg; Brian H Nathanson; Nicholas S Hannon; Jay S Steingrub; Peter K Lindenauer
Journal:  J Hosp Med       Date:  2014-04-09       Impact factor: 2.960

7.  Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data.

Authors:  Sameer S Kadri; Chanu Rhee; Jeffrey R Strich; Megan K Morales; Samuel Hohmann; Jonathan Menchaca; Anthony F Suffredini; Robert L Danner; Michael Klompas
Journal:  Chest       Date:  2016-07-22       Impact factor: 9.410

8.  Identifying patients with severe sepsis using administrative claims: patient-level validation of the angus implementation of the international consensus conference definition of severe sepsis.

Authors:  Theodore J Iwashyna; Andrew Odden; Jeffrey Rohde; Catherine Bonham; Latoya Kuhn; Preeti Malani; Lena Chen; Scott Flanders
Journal:  Med Care       Date:  2014-06       Impact factor: 2.983

9.  Treatment with neuromuscular blocking agents and the risk of in-hospital mortality among mechanically ventilated patients with severe sepsis.

Authors:  Jay S Steingrub; Tara Lagu; Michael B Rothberg; Brian H Nathanson; Karthik Raghunathan; Peter K Lindenauer
Journal:  Crit Care Med       Date:  2014-01       Impact factor: 7.598

10.  Use of noninvasive ventilation in patients with acute respiratory failure, 2000-2009: a population-based study.

Authors:  Allan J Walkey; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.